News

 
August 13, 2018, 5:00 am PST

Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board

Commences study to assess novel RORγt inhibitor for the treatment of psoriasis
Recruits key opinion leaders to guide clinical development of its RORγt programs

NIJMEGEN, The Netherlands and Encinitas, California, August 13, 2018 – Escalier Biosciences, BV, a privately held biopharmaceutical company and a leader in the field of immunology, today announced that the first patient has been dosed in a Phase 1/2a study evaluating ESR-114 topical gel in patients with mild-to-moderate psoriasis.

READ MORE
March 13, 2018, 6:00 am PST

Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases

Advancing Escalier’s drug candidates through human proof-of-concept studies

NIJMEGEN, The Netherlands and ENCINITAS, California, – Escalier Biosciences BV, a privately held biopharmaceutical company, today announced the closing of a $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topical and oral RORγt drug candidates for psoriasis and expects to be in the clinic with its topical compound in mid 2018.

READ MORE